Sigma Aldrich Corp (SIAL) 10-K Annual Report February 2012

Reported sales increased 5% to $610 million. Sales grew organically by 3% with Research and Fine Chemicals (“SAFC”) sales growing organically by 1% and 7%, respectively. Acquisitions contributed 2% to sales growth.

•

Net income was $108 million, up 15% from Q4 2010.

•

Reported diluted EPS was $0.89, up 17% from Q4 2010. Excluding a one-time tax item in 2011 adjusted EPS was $0.91 in Q4 2011.

Full Year 2011 Results

•

Sales grew 10% to $2.5 billion. Sales grew organically by 5% with Research and SAFC contributing 3% and 9% respectively to organic growth.

•

Net income was $457 million, up 19% from 2010.

•

Reported diluted EPS was $3.72, up 19% from 2010. Excluding restructuring, diluted adjusted EPS was $3.76, up 14% over the prior year.

•

2011 net cash provided by operating activities and free cash flow were $495 million and $391 million, respectively.

2012 Outlook (all percentages are compared to full year 2011 results)

•

Organic sales growth for the full year is expected to be in the mid single digit range assuming market conditions similar to late 2011, with lower sales growth in the first half of 2012 and higher sales growth later in the year. The recently completed acquisition of BioReliance Holdings, Inc. (“BioReliance”) is expected to increase 2012 sales growth by about 5%. At current exchange rates, currency rate changes are expected to reduce otherwise reportable sales growth for the full year by approximately 2%.

The following information was filed by Sigma Aldrich Corp (SIAL) on Thursday, February 9, 2012 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/90185/000119312512056253/d263565d10k.htm

View differences made from one year to another to evaluate Sigma Aldrich Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Sigma Aldrich Corp.

Continue

Assess how Sigma Aldrich Corp's management team is paid from their Annual Proxy

Sigma Aldrich Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2012 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Sigma Aldrich Corp provided additional information to their SEC Filing as exhibits

Exhibit 3.1: Articles Of Incorporation

Exhibit 21: Subsidaries Of The Registrant

Exhibit 23: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: SIAL
CIK: 90185
Form Type: 10-K Annual Report
Accession Number: 0001193125-12-056253
Submitted to the SEC: Mon Feb 13 2012 4:26:52 PM EST
Accepted by the SEC: Mon Feb 13 2012
Period: Saturday, December 31, 2011
Industry: Wholesale Chemicals And Allied Products